Start Over Please hold this item Export MARC Display Return To Browse
 
     
Record: Previous Record Next Record
Title Clinical dilemmas in inflammatory bowel disease [electronic resource] : new challenges / edited by Peter M. Irving ... [et al.].
Publication Info Chichester : Wiley-Blackwell, 2011.
Edition 2nd ed.



Descript xv, 268 p. : ill.
Edition 2nd ed.
Contents Contents: List of Contributors. Preface. Part 1: Genes and Phenotype in IBD. 1 Which will take us further in IBD - study of coding variation or epigenetics? ( Miles Parkes ). 2 IBD in different ethnic groups: same or different? ( Rupert W.L. Leong, Dorothy K.L. Chow and Christian P. Selinger ). Part 2: Bugs and IBD - good, bad or indifferent? 3 How does the risk of infection influence management of IBD around the world? ( Kiran K. Peddi and Ian Craig Lawrance ). 4 Travelling with IBD ( Ing Shian Soon and Gilaad Kaplan ). 5 What to do about hepatitis B and hepatitis C in patients with IBD ( Morven Cunningham and Graham R. Foster ). 6 CMV in IBD - passenger or pathogen? ( Ahmed Kandiel & Bret Lashner ). 7 Clostridium difficile in IBD: Impact, Prevention and Treatment ( Ashwin N. Ananthakrishnan and David G. Binion ). 8 Pre- and synbiotics: placebo or panacea ( James O. Lindsay ). 9 Worms - light at the end of their burrow? ( John Leung and Joel V. Weinstock ). 10 Do we really need to vaccinate all patients with IBD? ( Gauree Gupta and Gil Y. Melmed ). Part 3: Investigating IBD. 11 Biomarkers in IBD: myth or marvel? ( Richard B. Gearry, Andrew S. Day ). 12 Radiation exposure in IBD: how do we minimize the dangers? ( Owen J O'Connor, Alan N. Desmond, Fergus Shanahan and Michael M. Maher ). 13 Surveillance colonoscopy in UC - what's the best way to do it? ( Matt Rutter ). Part 4: Medical therapy. 5-ASA. 14 New 5ASAs: a tiny step or giant stride forward? (L. Campbell Levy). 15 Do 5ASAs prevent cancer? ( Richard Logan and Venkataraman Subramanian ). 16 Why do we still use 5-ASAs in Crohns disease? ( Stephen Hanauer, Henit Yanai, Emma Calabrese ). Steroids. 17 Steroids in Crohn's disease: do the benefits outweigh the dangers? ( A. Hillary Steinhart ). Immunomodulators. 18 Thioguanine nucleotide measurement: Non-adherent, shunter, under-dosed or resistant? ( Miles Sparrow ). 19 Thiopurines and the sun: what should be done? ( Conal M. Perrett, Jane M. McGregor, Catherine A. Harwood ). 20 Do thiopurines worsen risk and prognosis of cervical neoplasia? ( Jeremy D. Sanderson and Melissa A. Smith ). 21 Optimising use of methotrexate ( Anna Foley and Peter R. Gibson ). 22 Which calcineurin inhibitor and when? ( A. Barney Hawthorne ). Biologics. 23 Are all anti-TNF agents the same? ( Jennifer L. Jones ). 24 One drug or two: Do patients on biologics need concurrent immunomodulation? ( Glen A. Doherty and Adam S. Cheifetz ). 25 How do we identify patients needing early aggressive therapy and what should we use? ( Marc Ferrante and Severine Vermeire ). 26 What is the role of biologics in UC? ( Joanna K. Law and Brian Bressler ). 27 What can we do with Crohn's patients refractory to antiTNF therapy? ( David T. Rubin ). 28 Which EIMs respond to biologics? ( Tina A. Mehta and CS Probert ). 29 Use and abuse of biologics in pregnancy ( Marla C. Dubinsky ). 30 Is anti-TNF therapy safe to use in people with a history of malignancy? ( Mark Lust and Simon Travis ). 31 What and how should we tell patients about the risks of immunomodulators and biologics? ( Corey A Siegel ). 32 When, how and in whom should we stop biologics? ( Edouard Louis, Jacques Belaiche, Catherine Reenaers ). Part 5: Other treatments. 33 Avoiding drug interactions ( Tim Elliott and Peter M. Irving ). 34 Is there still a role for ursodeoxycholic acid treatment in patients with inflammatory bowel disease associated with primary sclerosing cholangitis? ( Emmanouil Sinakos & Keith Lindor ). 35 Stem cell transplantation for Crohn's: what's the risk-benefit ratio? ( Venkataraman Subramanian and Christopher J Hawkey ). 36 Complementary Therapy: Is There a Needle in the Haystack? ( Shane M. Devlin ). Part 6: Surgical Dilemmas in IBD. 37 Optimising IBD patients for surgery and recovery ( Jonathan Wilson and Alastair Windsor ). 38 Is surgery the best initial treatment for limited ileocaecal Crohn's disease? ( Tom Oresland ). 39 Laparoscopic or open surgery for IBD? ( Donna Appleton and Michael Hershman ). 40 Perianal Crohn's disease - optimal management ( David A. Schwartz and Norman R. Clark III ). 41 Does anti-TNF therapy increase the risk of Complications of surgery? ( Ming Valerie Lin, Wojciech Blonski and Gary R. Lichtenstein ). 42 Pouches for Indeterminate Colitis and Crohn's Disease: Act Now, Pay Later? ( Phillip Fleshner ). 43 Dealing with pouchitis ( Bo Shen and Simon McLaughlin ). Part 7: Unsolved issues in IBD. 44 Mucosal healing in IBD - does it matter? ( Geert D'Haens ). 45 Vitamin D in IBD: from genetics to bone health via cancer and immunology ( Helen M. Pappa and Richard J. Grand ). 46 Got Milk? Medication Use and Nursing in Women with IBD (Sunanda Kane). 47 Does stress matter? ( Robert Maunder ). 48 IBS is common in IBD: fact or fallacy? ( James Goodhand & David Rampton ). 49 So where is all the cancer? ( Judith E. Baars & C. Janneke van der Woude ). Part 8: Nutrition in IBD. 50 What should patients with IBD eat? ( Emile Richman, Keith Leiper, Jonathan Rhodes ). 51 Enteral Nutrition in Crohn's - Who for, When, How and Which Formula? ( R. Shamir and Ernest G. Seidman ). 52 Optimizing treatment of iron deficiency anemia ( Hermann Schulze and Axel Dignass ). Part 9: Management process. 53 IBD Standards: will they enhance patient care? ( Michael D. Kappelman ). 54 Your treatment won't work if the patient doesn't take it ( Rob Horne ). 55 Inflammatory Bowel Disease: What to tell your ED team ( Louise Langmead ). 56 Transitioning from pediatric to adult care ( Elizabeth J. Hait and Laurie N. Fishman ). 57 Medicolegal Pitfalls in Inflammatory Bowel Disease (IBD) Care ( William J. Tremaine ).
Note 400 annual accesses. UkHlHU
ISBN 9781444342543 (e-book)
Click on the terms below to find similar items in the catalogue
Subject Inflammatory bowel diseases.
Inflammatory bowel diseases -- Decision making.
Alt author Irving, Peter, 1970-
Descript xv, 268 p. : ill.
Edition 2nd ed.
Contents Contents: List of Contributors. Preface. Part 1: Genes and Phenotype in IBD. 1 Which will take us further in IBD - study of coding variation or epigenetics? ( Miles Parkes ). 2 IBD in different ethnic groups: same or different? ( Rupert W.L. Leong, Dorothy K.L. Chow and Christian P. Selinger ). Part 2: Bugs and IBD - good, bad or indifferent? 3 How does the risk of infection influence management of IBD around the world? ( Kiran K. Peddi and Ian Craig Lawrance ). 4 Travelling with IBD ( Ing Shian Soon and Gilaad Kaplan ). 5 What to do about hepatitis B and hepatitis C in patients with IBD ( Morven Cunningham and Graham R. Foster ). 6 CMV in IBD - passenger or pathogen? ( Ahmed Kandiel & Bret Lashner ). 7 Clostridium difficile in IBD: Impact, Prevention and Treatment ( Ashwin N. Ananthakrishnan and David G. Binion ). 8 Pre- and synbiotics: placebo or panacea ( James O. Lindsay ). 9 Worms - light at the end of their burrow? ( John Leung and Joel V. Weinstock ). 10 Do we really need to vaccinate all patients with IBD? ( Gauree Gupta and Gil Y. Melmed ). Part 3: Investigating IBD. 11 Biomarkers in IBD: myth or marvel? ( Richard B. Gearry, Andrew S. Day ). 12 Radiation exposure in IBD: how do we minimize the dangers? ( Owen J O'Connor, Alan N. Desmond, Fergus Shanahan and Michael M. Maher ). 13 Surveillance colonoscopy in UC - what's the best way to do it? ( Matt Rutter ). Part 4: Medical therapy. 5-ASA. 14 New 5ASAs: a tiny step or giant stride forward? (L. Campbell Levy). 15 Do 5ASAs prevent cancer? ( Richard Logan and Venkataraman Subramanian ). 16 Why do we still use 5-ASAs in Crohns disease? ( Stephen Hanauer, Henit Yanai, Emma Calabrese ). Steroids. 17 Steroids in Crohn's disease: do the benefits outweigh the dangers? ( A. Hillary Steinhart ). Immunomodulators. 18 Thioguanine nucleotide measurement: Non-adherent, shunter, under-dosed or resistant? ( Miles Sparrow ). 19 Thiopurines and the sun: what should be done? ( Conal M. Perrett, Jane M. McGregor, Catherine A. Harwood ). 20 Do thiopurines worsen risk and prognosis of cervical neoplasia? ( Jeremy D. Sanderson and Melissa A. Smith ). 21 Optimising use of methotrexate ( Anna Foley and Peter R. Gibson ). 22 Which calcineurin inhibitor and when? ( A. Barney Hawthorne ). Biologics. 23 Are all anti-TNF agents the same? ( Jennifer L. Jones ). 24 One drug or two: Do patients on biologics need concurrent immunomodulation? ( Glen A. Doherty and Adam S. Cheifetz ). 25 How do we identify patients needing early aggressive therapy and what should we use? ( Marc Ferrante and Severine Vermeire ). 26 What is the role of biologics in UC? ( Joanna K. Law and Brian Bressler ). 27 What can we do with Crohn's patients refractory to antiTNF therapy? ( David T. Rubin ). 28 Which EIMs respond to biologics? ( Tina A. Mehta and CS Probert ). 29 Use and abuse of biologics in pregnancy ( Marla C. Dubinsky ). 30 Is anti-TNF therapy safe to use in people with a history of malignancy? ( Mark Lust and Simon Travis ). 31 What and how should we tell patients about the risks of immunomodulators and biologics? ( Corey A Siegel ). 32 When, how and in whom should we stop biologics? ( Edouard Louis, Jacques Belaiche, Catherine Reenaers ). Part 5: Other treatments. 33 Avoiding drug interactions ( Tim Elliott and Peter M. Irving ). 34 Is there still a role for ursodeoxycholic acid treatment in patients with inflammatory bowel disease associated with primary sclerosing cholangitis? ( Emmanouil Sinakos & Keith Lindor ). 35 Stem cell transplantation for Crohn's: what's the risk-benefit ratio? ( Venkataraman Subramanian and Christopher J Hawkey ). 36 Complementary Therapy: Is There a Needle in the Haystack? ( Shane M. Devlin ). Part 6: Surgical Dilemmas in IBD. 37 Optimising IBD patients for surgery and recovery ( Jonathan Wilson and Alastair Windsor ). 38 Is surgery the best initial treatment for limited ileocaecal Crohn's disease? ( Tom Oresland ). 39 Laparoscopic or open surgery for IBD? ( Donna Appleton and Michael Hershman ). 40 Perianal Crohn's disease - optimal management ( David A. Schwartz and Norman R. Clark III ). 41 Does anti-TNF therapy increase the risk of Complications of surgery? ( Ming Valerie Lin, Wojciech Blonski and Gary R. Lichtenstein ). 42 Pouches for Indeterminate Colitis and Crohn's Disease: Act Now, Pay Later? ( Phillip Fleshner ). 43 Dealing with pouchitis ( Bo Shen and Simon McLaughlin ). Part 7: Unsolved issues in IBD. 44 Mucosal healing in IBD - does it matter? ( Geert D'Haens ). 45 Vitamin D in IBD: from genetics to bone health via cancer and immunology ( Helen M. Pappa and Richard J. Grand ). 46 Got Milk? Medication Use and Nursing in Women with IBD (Sunanda Kane). 47 Does stress matter? ( Robert Maunder ). 48 IBS is common in IBD: fact or fallacy? ( James Goodhand & David Rampton ). 49 So where is all the cancer? ( Judith E. Baars & C. Janneke van der Woude ). Part 8: Nutrition in IBD. 50 What should patients with IBD eat? ( Emile Richman, Keith Leiper, Jonathan Rhodes ). 51 Enteral Nutrition in Crohn's - Who for, When, How and Which Formula? ( R. Shamir and Ernest G. Seidman ). 52 Optimizing treatment of iron deficiency anemia ( Hermann Schulze and Axel Dignass ). Part 9: Management process. 53 IBD Standards: will they enhance patient care? ( Michael D. Kappelman ). 54 Your treatment won't work if the patient doesn't take it ( Rob Horne ). 55 Inflammatory Bowel Disease: What to tell your ED team ( Louise Langmead ). 56 Transitioning from pediatric to adult care ( Elizabeth J. Hait and Laurie N. Fishman ). 57 Medicolegal Pitfalls in Inflammatory Bowel Disease (IBD) Care ( William J. Tremaine ).
Note 400 annual accesses. UkHlHU
ISBN 9781444342543 (e-book)
Subject Inflammatory bowel diseases.
Inflammatory bowel diseases -- Decision making.
Alt author Irving, Peter, 1970-

Subject Inflammatory bowel diseases.
Inflammatory bowel diseases -- Decision making.
Descript xv, 268 p. : ill.
Contents Contents: List of Contributors. Preface. Part 1: Genes and Phenotype in IBD. 1 Which will take us further in IBD - study of coding variation or epigenetics? ( Miles Parkes ). 2 IBD in different ethnic groups: same or different? ( Rupert W.L. Leong, Dorothy K.L. Chow and Christian P. Selinger ). Part 2: Bugs and IBD - good, bad or indifferent? 3 How does the risk of infection influence management of IBD around the world? ( Kiran K. Peddi and Ian Craig Lawrance ). 4 Travelling with IBD ( Ing Shian Soon and Gilaad Kaplan ). 5 What to do about hepatitis B and hepatitis C in patients with IBD ( Morven Cunningham and Graham R. Foster ). 6 CMV in IBD - passenger or pathogen? ( Ahmed Kandiel & Bret Lashner ). 7 Clostridium difficile in IBD: Impact, Prevention and Treatment ( Ashwin N. Ananthakrishnan and David G. Binion ). 8 Pre- and synbiotics: placebo or panacea ( James O. Lindsay ). 9 Worms - light at the end of their burrow? ( John Leung and Joel V. Weinstock ). 10 Do we really need to vaccinate all patients with IBD? ( Gauree Gupta and Gil Y. Melmed ). Part 3: Investigating IBD. 11 Biomarkers in IBD: myth or marvel? ( Richard B. Gearry, Andrew S. Day ). 12 Radiation exposure in IBD: how do we minimize the dangers? ( Owen J O'Connor, Alan N. Desmond, Fergus Shanahan and Michael M. Maher ). 13 Surveillance colonoscopy in UC - what's the best way to do it? ( Matt Rutter ). Part 4: Medical therapy. 5-ASA. 14 New 5ASAs: a tiny step or giant stride forward? (L. Campbell Levy). 15 Do 5ASAs prevent cancer? ( Richard Logan and Venkataraman Subramanian ). 16 Why do we still use 5-ASAs in Crohns disease? ( Stephen Hanauer, Henit Yanai, Emma Calabrese ). Steroids. 17 Steroids in Crohn's disease: do the benefits outweigh the dangers? ( A. Hillary Steinhart ). Immunomodulators. 18 Thioguanine nucleotide measurement: Non-adherent, shunter, under-dosed or resistant? ( Miles Sparrow ). 19 Thiopurines and the sun: what should be done? ( Conal M. Perrett, Jane M. McGregor, Catherine A. Harwood ). 20 Do thiopurines worsen risk and prognosis of cervical neoplasia? ( Jeremy D. Sanderson and Melissa A. Smith ). 21 Optimising use of methotrexate ( Anna Foley and Peter R. Gibson ). 22 Which calcineurin inhibitor and when? ( A. Barney Hawthorne ). Biologics. 23 Are all anti-TNF agents the same? ( Jennifer L. Jones ). 24 One drug or two: Do patients on biologics need concurrent immunomodulation? ( Glen A. Doherty and Adam S. Cheifetz ). 25 How do we identify patients needing early aggressive therapy and what should we use? ( Marc Ferrante and Severine Vermeire ). 26 What is the role of biologics in UC? ( Joanna K. Law and Brian Bressler ). 27 What can we do with Crohn's patients refractory to antiTNF therapy? ( David T. Rubin ). 28 Which EIMs respond to biologics? ( Tina A. Mehta and CS Probert ). 29 Use and abuse of biologics in pregnancy ( Marla C. Dubinsky ). 30 Is anti-TNF therapy safe to use in people with a history of malignancy? ( Mark Lust and Simon Travis ). 31 What and how should we tell patients about the risks of immunomodulators and biologics? ( Corey A Siegel ). 32 When, how and in whom should we stop biologics? ( Edouard Louis, Jacques Belaiche, Catherine Reenaers ). Part 5: Other treatments. 33 Avoiding drug interactions ( Tim Elliott and Peter M. Irving ). 34 Is there still a role for ursodeoxycholic acid treatment in patients with inflammatory bowel disease associated with primary sclerosing cholangitis? ( Emmanouil Sinakos & Keith Lindor ). 35 Stem cell transplantation for Crohn's: what's the risk-benefit ratio? ( Venkataraman Subramanian and Christopher J Hawkey ). 36 Complementary Therapy: Is There a Needle in the Haystack? ( Shane M. Devlin ). Part 6: Surgical Dilemmas in IBD. 37 Optimising IBD patients for surgery and recovery ( Jonathan Wilson and Alastair Windsor ). 38 Is surgery the best initial treatment for limited ileocaecal Crohn's disease? ( Tom Oresland ). 39 Laparoscopic or open surgery for IBD? ( Donna Appleton and Michael Hershman ). 40 Perianal Crohn's disease - optimal management ( David A. Schwartz and Norman R. Clark III ). 41 Does anti-TNF therapy increase the risk of Complications of surgery? ( Ming Valerie Lin, Wojciech Blonski and Gary R. Lichtenstein ). 42 Pouches for Indeterminate Colitis and Crohn's Disease: Act Now, Pay Later? ( Phillip Fleshner ). 43 Dealing with pouchitis ( Bo Shen and Simon McLaughlin ). Part 7: Unsolved issues in IBD. 44 Mucosal healing in IBD - does it matter? ( Geert D'Haens ). 45 Vitamin D in IBD: from genetics to bone health via cancer and immunology ( Helen M. Pappa and Richard J. Grand ). 46 Got Milk? Medication Use and Nursing in Women with IBD (Sunanda Kane). 47 Does stress matter? ( Robert Maunder ). 48 IBS is common in IBD: fact or fallacy? ( James Goodhand & David Rampton ). 49 So where is all the cancer? ( Judith E. Baars & C. Janneke van der Woude ). Part 8: Nutrition in IBD. 50 What should patients with IBD eat? ( Emile Richman, Keith Leiper, Jonathan Rhodes ). 51 Enteral Nutrition in Crohn's - Who for, When, How and Which Formula? ( R. Shamir and Ernest G. Seidman ). 52 Optimizing treatment of iron deficiency anemia ( Hermann Schulze and Axel Dignass ). Part 9: Management process. 53 IBD Standards: will they enhance patient care? ( Michael D. Kappelman ). 54 Your treatment won't work if the patient doesn't take it ( Rob Horne ). 55 Inflammatory Bowel Disease: What to tell your ED team ( Louise Langmead ). 56 Transitioning from pediatric to adult care ( Elizabeth J. Hait and Laurie N. Fishman ). 57 Medicolegal Pitfalls in Inflammatory Bowel Disease (IBD) Care ( William J. Tremaine ).
Note 400 annual accesses. UkHlHU
Alt author Irving, Peter, 1970-
ISBN 9781444342543 (e-book)

Links and services for this item: